Becton, Dickinson and Company (NYSE:BDX) Position Trimmed by Garrison Asset Management LLC

Garrison Asset Management LLC trimmed its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 1.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 13,940 shares of the medical instruments supplier’s stock after selling 139 shares during the quarter. Becton, Dickinson and Company comprises 1.7% of Garrison Asset Management LLC’s portfolio, making the stock its 21st largest position. Garrison Asset Management LLC’s holdings in Becton, Dickinson and Company were worth $3,361,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in BDX. WR Wealth Planners LLC lifted its holdings in shares of Becton, Dickinson and Company by 1.4% in the second quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock valued at $696,000 after buying an additional 42 shares during the period. Clear Creek Financial Management LLC lifted its stake in shares of Becton, Dickinson and Company by 5.1% in the 2nd quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock valued at $210,000 after purchasing an additional 44 shares during the last quarter. Sound Income Strategies LLC lifted its holdings in shares of Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 44 shares during the last quarter. Central Pacific Bank Trust Division grew its position in Becton, Dickinson and Company by 22.5% in the 3rd quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock worth $59,000 after purchasing an additional 45 shares during the last quarter. Finally, Capital Advisors Ltd. LLC increased its stake in Becton, Dickinson and Company by 3.6% during the second quarter. Capital Advisors Ltd. LLC now owns 1,394 shares of the medical instruments supplier’s stock valued at $326,000 after acquiring an additional 48 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

BDX has been the subject of a number of recent analyst reports. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their target price for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Stifel Nicolaus raised their price objective on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Raymond James decreased their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. Finally, Evercore ISI upped their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $282.63.

Becton, Dickinson and Company Stock Up 0.3 %

Shares of BDX stock traded up $0.61 on Monday, hitting $235.85. The stock had a trading volume of 161,186 shares, compared to its average volume of 1,365,774. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $259.92. The stock has a market cap of $68.17 billion, a price-to-earnings ratio of 48.40, a price-to-earnings-growth ratio of 1.75 and a beta of 0.43. The business has a 50 day moving average of $237.56 and a 200 day moving average of $235.09. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, beating the consensus estimate of $3.31 by $0.19. The firm had revenue of $4.99 billion for the quarter, compared to analysts’ expectations of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The company’s revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the business posted $2.96 earnings per share. As a group, analysts expect that Becton, Dickinson and Company will post 13.11 EPS for the current year.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.